Abstract
Purpose. To prepare and characterize a reversibly lipidized dipalmitoyl desmopressin (DPP), and to compare its anti-diuretic efficacy and biodistribution with that of unmodified desmopressin (DDAVP).
Methods. Dithiothreitol (DTT) was used to reduce the intramolecular disulfide bond in DDAVP, and the reduced DDAVP was treated with a thiopyridine-containing disulfide lipidization reagent, Pal-CPD. The product, DPP, was purified by acid precipitation and, subsequently, by size-exclusion chromatography. Reversed-phase HPLC was used to analyze the purity and to evaluate the hydrophobicity of the product. Mass spectrometry was employed to characterize its molecular structure. The biological activity of DPP was demonstrated by the anti-diuretic effects in vasopressin-deficient Brattleboro rats. Preliminary pharmacokinetic and biodistribution studies of intravenously injected DDAVP and DPP were carried out in CF-1 mice.
Results. DDAVP was readily reduced by a 2-fold molar excess of DTT at 37°C for 0.5 hr. DPP was formed by the reaction of reduced DDAVP with Pal-CPD. Each DPP molecule contains two palmitic acid moieties, which link to the peptide via two disulfide bonds. After acid precipitation and size-exclusion chromatography, the purity was found to be approximately 95%, and the overall yield was 57%. When DPP was administered subcutaneously to Brattleboro rats, the potency of the anti-diuretic activity of DDAVP was enhanced to more than 250-fold. The plasma concentration of intravenously injected DDAVP in mice decreased rapidly during the first 20 min and followed by a slow elimination rate. However, in DPP administered mice, the plasma concentration actually increased in the first 20 min, followed by a slow elimination with a rate similar to that in DDAVP-injected mice. The regeneration of DDAVP was detected in the plasma of mice treated with DPP. Studies of the organ distribution in mice indicated that the liver retention of DPP was longer than that of DDAVP. On the other hand, the intestinal excretion of DPP was significantly less than that of DDAVP.
Conclusions. The 250-fold increase of the anti-diuretic potency in DPP is most likely due to a slow elimination and prolonged tissue retention, together with the regeneration of active DDAVP, in the animals. Our results indicate that reversible lipidization is a simple and effective approach for improving the efficacy of many peptide drugs.
Similar content being viewed by others
REFERENCES
V. H. L. Lee (ed). Peptide and Protein Drug Delivery, Marcel Dekker, Inc., New York, 1990.
S. Frøkjær, L. Christrup, and P. Krogsgaard-Larsen (eds). Peptide and Protein Drug Delivery, Munksgaard, Copenhagen, 1998.
J. L. Cleland, O. L. Johnson, S. Puttney, and A. J. S. Jones. Recombinant human growth hormone poly (lactic-co-glycolic acid) microsphere formulation development. Adv. Drug Del. Rev. 28:71–84 (1997).
S. Muranish, A. Sakai, K. Yamada, M. Murakami, K. Takada, and Y. Kiso. Lipophilic peptides: synthesis of lauroyl thyrotropin-releasing hormone and its biological activity. Pharm. Res. 8:649–652 (1991).
E. Yodoya, K. Uemura, T. Tenma, T. Fujita, M. Murakami, A. Yamamoto, and S. Muranishi. Enhanced permeation of tetragastrin across the rat intestinal membrane and its reduced degradation by acylation with various fatty acids. J. Pharmacol. Exp. Ther. 271:1509–1513 (1994).
M. Hashizume, T. Douen, M. Murakami, A. Yamamoto, K. Takada, and S. Muranishi. Improvement of large intestinal absorption of insulin by chemical modification with palmitic acid in rats. J. Pharm. Pharmacol. 44:555–559 (1992).
K. Y. Hostetler, D. D. Richman, E. A. Forssen, L. Selk, R. Basava, M. F. Gardner, S. Parker, and C. Basava. Phospholipid prodrug inhibitors of the HIV protease. Biochem. Pharmacol. 48:1399–1404 (1994).
H. Bundgaard and J. Møss. Prodrugs of peptides. 6. Bioreversible derivatives of thyrotropin-releasing hormone (TRH) with increased lipophilicity and resistance to cleavage by the TRH-specific serum enzyme. Pharm. Res. 7:885–892, 1990.
V. P. Chekhonin, I. A. Ryabukhin, Y. A. Zhirkov, I. A. Kashparov, and T. B. Dmitriyeva. Transport of hydrophobized fragments of antibodies through the blood-brain barrier. Neuroreport 7:129–132, 1995.
H. Asada, T. Douen, Y. Mizokoshi, T. Fujita, M. Murakami, A. Yamamoto, and S. Muranishi. Stability of acyl derivatives of insulin in the small intestine: Relative importance of insulin association characteristics in aqueous solution. Pharm. Res. 11:1115–1120, 1994.
L. Honeycutt, J. Wang, H. Ekrami, and W. C. Shen. Comparison of pharmacokinetic parameters of a polypeptide, the Bowman-Birk protease inhibitor (BBI), and its palmitic acid conjugate. Pharm. Res. 13:1373–1377 (1996).
M. Hashimoto, K. Takada, Y. Kiso, and S. Muranishi. Synthesis of palmitoyl derivatives of insulin and their biological activities. Pharm Res. 6:171–176 (1989).
H. Ekrami, A. R. Kennedy, and W. C. Shen. Water-soluble fatty acid derivatives as acylating agents for reversible lipidization of polypeptides. FEBS Lett. 371:283–186, (1995).
Desmopressin acetate. In Drug Facts and Comparisons (53 rd ed), Wolters Kluwer Co., St. Louis, MI, 1999, pp. 545–547.
H. Weingartner, P. Gold, J. C. Ballenger, S. A. Smallberg, R. Summers, D. R. Rubinow, R. M. Post, and F. K. Goodwin. Effects of vasopressin on human memory functions. Science 211:601–603 (1981).
I. Vavra, A. Machová, V. Holecek, J. H. Cort, M. Zaoral, and F. Sorm. Effect of a synthetic analogue of vasopressin in animals and in patients with diabetes insipidus. Lancet 1:948–952 (1968).
M. Manning, L. Balaspiri, and J. Moehring. Synthesis and some pharmacological properties of deamino [4-threonine, 8-D-arginine] vasopressin and deamino [8-D-arginine] vasopressin, highly potent and specific antidiuretic peptides, and [8-D-arginine] vasopressin and deamino-arginine-vasopressin. J. Med. Chem. 19:842–845 (1976).
H. W. Sokol and H. Valtin (eds) The Brattleboro Rat (Ann. N.Y. Acad. Sci. 394), 1982.
P. C. McConahey and F. J. Dixon. Radiation of proteins by the use of the chloramine-T method. Meth. Enzymol. 70:221–247 (1980).
F. A. Lázló, T. Janáky, L. Balaspiri, and J.-L. Morgat. Biological half-life and organ distribution of [3H] 1-deamino-8-D-arginine-vasopressin in the rat. J. Endocrinol. 88:181–186 (1981).
D. A. Langs, G. D. Smith, and J. J. Stezowski. Structure of pressinoic acid: the cyclic moiety of vasopressin. Science 232:1240–1242 (1986).
W. C. Shen, J. Wang, and D. Shen. Reversible lipidization for the delivery of peptide amd protein drugs. In S. Frøkjær, L. Christrup, and P. Krogsgaard-Larsen (eds), Peptide and Protein Drug Delivery, Munksgaard, Copenhagen, 1998, pp. 397–408.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wang, J., Shen, D. & Shen, WC. Preparation, Purification, and Characterization of a Reversibly Lipidized Desmopressin with Potentiated Anti-Diuretic Activity. Pharm Res 16, 1674–1679 (1999). https://doi.org/10.1023/A:1018929312715
Issue Date:
DOI: https://doi.org/10.1023/A:1018929312715